Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Zobeida Cruz‐Monserrate

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0849-655X; OpenAlex author ID A5004563285; NIH RePORTER profile ID 6124579. Sources: OpenAlex.

Their work

Papers
33 (first author 3, last author 9)
Trials
0
Grants
3
Labs led
2
Collaborators
134
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: 5 papers · 2018: 4 papers · 2019: 4 papers · 2020: 1 paper · 2021: 2 papers · 2022: 3 papers, 2 grants · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 3 papers, 1 grant

Papers 33

  1. Lack of tumor-derived LCN2 sensitizes pancreatic cancer cells to ferroptosis induction. Last author DOI 10.1016/j.canlet.2026.218823↗
  2. Adult Chronic Pancreatitis Working Group: Goals, Accomplishments and the Path Ahead. A Report From the Consortium for the Study of Chronic Pancreatitis, Diabet… Co-author DOI 10.1097/mpa.0000000000002657↗
  3. Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming. Last author DOI 10.1158/0008-5472.can-25-2379↗
  4. MG53 suppresses tumor growth via transcriptional inhibition of KIF11 in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2024.102118↗
  5. Physical Activity Decreases Inflammation and Delays the Development of Obesity-Associated Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/0008-5472.can-23-1045↗
  6. The Role of Genetic, Metabolic, Inflammatory, and Immunologic Mediators in the Progression of Intraductal Papillary Mucinous Neoplasms to Pancreatic Adenocarci… Co-author DOI 10.3390/cancers15061722↗
  7. A review of physical activity in pancreatic ductal adenocarcinoma: Epidemiology, intervention, animal models, and clinical trials. Last author DOI 10.1016/j.pan.2021.10.004↗
  8. Altered Plasma Fatty Acid Abundance Is Associated with Cachexia in Treatment-Naïve Pancreatic Cancer. Last author DOI 10.3390/cells11050910↗
  9. The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer. Co-author DOI 10.3390/ijms23137066↗
  10. Dietary Patterns of Insulinemia, Inflammation and Glycemia, and Pancreatic Cancer Risk: Findings from the Women's Health Initiative. Co-author DOI 10.1158/1055-9965.epi-20-1478↗
  11. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic… Co-author DOI 10.1158/1078-0432.ccr-20-1422↗
  12. Iron and Lipocalin-2 Modulate Cellular Responses in the Tumor Micro-environment of Pancreatic Ductal Adenocarcinoma Last author DOI 10.1101/2020.01.14.907188↗
  13. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.11.002↗
  14. Cathepsin E expression and activity: Role in the detection and treatment of pancreatic cancer. Last author DOI 10.1016/j.pan.2019.09.009↗
  15. Animal Models: Challenges and Opportunities to Determine Optimal Experimental Models of Pancreatitis and Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001335↗
  16. Prolactin Promotes Fibrosis and Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-18-3064↗
  17. Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer. First author DOI 10.1016/j.jand.2017.07.005↗
  18. The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and D… Co-author DOI 10.1097/mpa.0000000000001037↗
  19. Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pan… First author DOI 10.1097/mpa.0000000000001171↗
  20. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-311585↗
  21. Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53. Co-author DOI 10.1038/onc.2016.461↗
  22. Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions. Co-author DOI 10.1097/mpa.0000000000000898↗
  23. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. Last author DOI 10.1158/0008-5472.can-16-1986↗
  24. miR-202 Diminishes TGFβ Receptors and Attenuates TGFβ1-Induced EMT in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-16-0327↗
  25. The Burden of Systemic Adiposity on Pancreatic Disease: Acute Pancreatitis, Non-Alcoholic Fatty Pancreas Disease, and Pancreatic Cancer. Co-author PMID 29491829↗
  26. The Impact of Obesity on Gallstone Disease, Acute Pancreatitis, and Pancreatic Cancer. Co-author DOI 10.1016/j.gtc.2016.07.010↗
  27. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Co-author DOI 10.1016/s2468-1253(16)30106-6↗
  28. Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression. Co-author DOI 10.18632/oncotarget.3499↗
  29. Targeting pancreatic ductal adenocarcinoma acidic microenvironment. Co-author DOI 10.1038/srep04410↗
  30. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-14-0028↗
  31. Pancreatic cancer-associated Cathepsin E as a drug activator. First author DOI 10.1016/j.jconrel.2013.02.007↗
  32. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Last author DOI 10.1053/j.gastro.2013.08.018↗
  33. Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models. Co-author DOI 10.1136/gutjnl-2011-300544↗

Grants 3

  1. Contributions of the Adipose Tissue to the Development of Pancreatic Cancer R01CA279707↗
  2. Polyunsaturated fatty acids supplementation and Lipocalin 2 blockade in preventing pancreatic cancer R01CA223204↗
  3. Mediators of Pancreatic Cancer-Associated Cachexia R21CA256409↗

Closest collaborators

The 25 strongest of 134 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Valentina Pita-Grisanti · 6 shared papers, 2020–2026 · strength 1.04
  2. Kristyn Gumpper · 6 shared papers, 2020–2026 · strength 1.04
  3. Darwin Lewis Conwell · 9 shared papers, 2016–2026 · strength 0.94
  4. Phil A. Hart · 9 shared papers, 2016–2026 · strength 0.89
  5. Hsiang‐Yin Hsueh · 4 shared papers, 2022–2026 · strength 0.81
  6. Ericka Vélez-Bonet · 3 shared papers, 2024–2026 · strength 0.63
  7. Somashekar Gopala Krishna · 6 shared papers, 2016–2023 · strength 0.63
  8. Stephen Jacob Pandol · 6 shared papers, 2016–2026 · strength 0.55
  9. Thomas A. Mace · 6 shared papers, 2017–2024 · strength 0.51
  10. Dana K. Andersen · 4 shared papers, 2016–2026 · strength 0.42
  11. Craig D. Logsdon · 8 shared papers, 2012–2018 · strength 0.36
  12. Dhiraj Yadav · 3 shared papers, 2016–2026 · strength 0.34
  13. Jami Lynn Saloman · 2 shared papers, 2019–2026 · strength 0.30
  14. Mark D. Topazian · 2 shared papers, 2018–2026 · strength 0.28
  15. José Serrano · 2 shared papers, 2018–2026 · strength 0.28
  16. Melena D. Bellin · 2 shared papers, 2016–2026 · strength 0.28
  17. Christopher E Forsmark · 2 shared papers, 2016–2026 · strength 0.28
  18. Tanios Bekaii‐Saab · 4 shared papers, 2017–2019 · strength 0.25
  19. Mary E. Dillhoff · 3 shared papers, 2017–2022 · strength 0.25
  20. Gregory B. Lesinski · 4 shared papers, 2017–2019 · strength 0.25
  21. Andrew J. Gunderson · 1 shared paper, 2026 · strength 0.24
  22. Florencia M. McAllister · 1 shared paper, 2026 · strength 0.24
  23. Chuanxi Cai · 1 shared paper, 2024 · strength 0.23
  24. Xiaoliang Wang · 1 shared paper, 2024 · strength 0.23
  25. Allan Tsung · 1 shared paper, 2024 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.